^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

Published date:
05/27/2020
Excerpt:
In two patients with progressive disease, genomic profiling demonstrated a cMET exon 14 mutation + KRAS G12A mutation in one case, and a persisting ROS1-CD74 fusion + TP53 K139N, FGFR2 E250G, ATM G2695D, and NF1 R2258Q mutations in the other.
DOI:
10.1007/s12094-020-02376-w